Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Syndax Pharmaceuticals Inc (SNDX)
|
Add to portfolio |
|
|
|
| Price: |
$20.60
| | Metrics |
| OS: |
69.5
|
M
| |
-43
|
% ROE
|
| Market cap: |
$1.43
|
B
| |
-56
|
% ROIC
|
|
Net cash:
|
$97.3
|
M
| |
$1.40
|
per share
|
|
EV:
|
$1.33
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
($171)
|
M
| |
|
|
| EPS |
($85,742.23)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 0.0 | 139.7 | 1.5 | 1.5 | 1.5 | 2.1 | 1.2 | 0.6 |
| Revenue growth | -100.0% | 9109.6% | 0.0% | 0.0% | -28.0% | 72.8% | 94.6% | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 0.0 | 139.7 | 1.5 | 1.5 | 1.5 | 2.1 | 1.2 | 0.6 |
| Gross margin | | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Selling, general and administrative | 151.8 | 113.5 | 72.9 | | | | | |
| Research and development | | | | 43.0 | 60.1 | 48.2 | 31.7 | 9.5 |
| General and administrative | | | | 16.1 | 17.3 | 15.9 | 13.3 | 11.6 |
| EBIT | -149.3 | 24.9 | -73.2 | -57.5 | -75.9 | -62.0 | -43.8 | -20.5 |
| EBIT margin | | 17.8% | -4822.5% | -3792.9% | -5001.7% | -2939.0% | -3587.4% | -3271.6% |
| Pre-tax income | -149.3 | 24.9 | -73.2 | -56.0 | -74.0 | -60.8 | -44.5 | -24.1 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -149.3 | 24.9 | -73.2 | -56.0 | -74.0 | -60.8 | -47.1 | -103.8 |
| Net margin | | 17.8% | -4822.5% | -3694.6% | -4875.5% | -2884.3% | -3858.2% | -16562.2% |
| |
| Diluted EPS | ($2.46) | $0.46 | ($1.77) | ($1.84) | ($2.92) | ($2.90) | ($3.22) | ($1,519.27) |
| Shares outstanding (diluted) | 60.8 | 53.6 | 41.3 | 30.5 | 25.4 | 21.0 | 14.6 | 0.1 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|